近期,一家上半年无收入、无利润的生物科技公司在港股市场掀起了血雨腥风。从暴涨到暴跌,药捷安康仅用三天时间,就走完了某龙头创新药企曾经长达两年的股价起伏。在这场资本博弈中,有人赚得盆满钵满,也有人血本无归。刀口舔血的游戏里,赢家终究是少数。被动卷入的基民同样难以幸免,部分ETF资金高位接盘,深陷套牢困境。药捷安康引发的这场资本狂欢,为原本就已炽热的港股18A(采用港交所第18A章规则上市的未有收入、...
Source Link近期,一家上半年无收入、无利润的生物科技公司在港股市场掀起了血雨腥风。从暴涨到暴跌,药捷安康仅用三天时间,就走完了某龙头创新药企曾经长达两年的股价起伏。在这场资本博弈中,有人赚得盆满钵满,也有人血本无归。刀口舔血的游戏里,赢家终究是少数。被动卷入的基民同样难以幸免,部分ETF资金高位接盘,深陷套牢困境。药捷安康引发的这场资本狂欢,为原本就已炽热的港股18A(采用港交所第18A章规则上市的未有收入、...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.